Acurx Pharmaceuticals, Inc. (ACXP) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
13/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseACXP / S&P -58.22% / 15.20% |
LoseACXP / S&P ACXP unavailable / 15.00% |
LoseACXP / S&P -74.88% / 50.40% |
| 2026-Q11/3 |
WinACXP / S&P 49.00% / -4.33% |
LoseACXP / S&P ACXP unavailable / 11.30% |
LoseACXP / S&P -71.13% / 27.70% |
| 2025-Q40/3 |
LoseACXP / S&P -41.96% / 2.65% |
LoseACXP / S&P ACXP unavailable / 9.00% |
LoseACXP / S&P -54.11% / 13.40% |
| 2025-Q30/3 |
LoseACXP / S&P -58.02% / 8.12% |
LoseACXP / S&P ACXP unavailable / 4.61% |
LoseACXP / S&P -8.91% / 13.45% |
| 2025-Q22/3 |
WinACXP / S&P 31.03% / 10.94% |
LoseACXP / S&P ACXP unavailable / 4.83% |
WinACXP / S&P 75.29% / 10.63% |
| 2025-Q11/3 |
LoseACXP / S&P -52.09% / -4.27% |
LoseACXP / S&P ACXP unavailable / 4.98% |
WinACXP / S&P 1088.98% / 10.57% |
| 2024-Q41/3 |
LoseACXP / S&P -57.16% / 2.41% |
LoseACXP / S&P ACXP unavailable / 5.25% |
WinACXP / S&P 957.39% / 6.15% |
| 2024-Q31/3 |
LoseACXP / S&P -15.56% / 5.89% |
LoseACXP / S&P ACXP unavailable / 5.89% |
WinACXP / S&P 787.62% / 6.11% |
| 2024-Q21/3 |
LoseACXP / S&P -8.16% / 4.28% |
LoseACXP / S&P ACXP unavailable / 5.38% |
WinACXP / S&P 440.71% / 5.12% |
| 2024-Q11/3 |
LoseACXP / S&P -36.03% / 10.56% |
LoseACXP / S&P ACXP unavailable / 5.71% |
WinACXP / S&P 6.31% / 5.59% |
| 2023-Q41/3 |
WinACXP / S&P 155.33% / 11.69% |
LoseACXP / S&P ACXP unavailable / 6.81% |
LoseACXP / S&P 2.68% / 7.78% |
| 2023-Q31/3 |
LoseACXP / S&P -43.40% / -3.27% |
LoseACXP / S&P ACXP unavailable / 7.52% |
WinACXP / S&P -0.94% / -5.03% |
| 2023-Q21/3 |
LoseACXP / S&P -23.41% / 8.74% |
LoseACXP / S&P ACXP unavailable / 9.50% |
WinACXP / S&P -5.83% / -8.57% |
| 2023-Q10/3 |
LoseACXP / S&P -13.07% / 7.50% |
LoseACXP / S&P ACXP unavailable / 10.77% |
LoseACXP / S&P -26.49% / -15.69% |
| 2022-Q41/3 |
WinACXP / S&P 32.67% / 7.56% |
LoseACXP / S&P ACXP unavailable / 11.88% |
LoseACXP / S&P -23.29% / -17.99% |
| 2022-Q30/3 |
LoseACXP / S&P -20.84% / -4.88% |
LoseACXP / S&P ACXP unavailable / 13.47% |
LoseACXP / S&P -24.29% / -1.41% |
| 2022-Q21/3 |
WinACXP / S&P 15.55% / -16.10% |
LoseACXP / S&P ACXP unavailable / 13.71% |
LoseACXP / S&P 4.35% / 11.04% |
| 2022-Q10/3 |
LoseACXP / S&P -24.09% / -4.60% |
LoseACXP / S&P ACXP unavailable / 15.97% |
LoseACXP / S&P ACXP unavailable / 42.23% |
| 2021-Q40/3 |
LoseACXP / S&P -15.93% / 11.03% |
LoseACXP / S&P ACXP unavailable / 15.00% |
LoseACXP / S&P ACXP unavailable / 96.40% |
| 2021-Q30/3 |
LoseACXP / S&P -19.44% / 0.58% |
LoseACXP / S&P ACXP unavailable / 10.77% |
LoseACXP / S&P ACXP unavailable / 69.42% |
| 2021-Q20/3 |
LoseACXP / S&P ACXP unavailable / 8.55% |
LoseACXP / S&P ACXP unavailable / 6.58% |
LoseACXP / S&P ACXP unavailable / 51.81% |
| 2021-Q10/3 |
LoseACXP / S&P ACXP unavailable / 6.17% |
LoseACXP / S&P ACXP unavailable / -1.06% |
LoseACXP / S&P ACXP unavailable / 7.39% |
| 2020-Q40/3 |
LoseACXP / S&P ACXP unavailable / 12.15% |
LoseACXP / S&P ACXP unavailable / -3.72% |
LoseACXP / S&P ACXP unavailable / -33.42% |
| 2020-Q30/3 |
LoseACXP / S&P ACXP unavailable / 8.93% |
LoseACXP / S&P ACXP unavailable / -2.04% |
LoseACXP / S&P ACXP unavailable / -27.10% |
| 2020-Q20/3 |
LoseACXP / S&P ACXP unavailable / 20.54% |
LoseACXP / S&P ACXP unavailable / -0.46% |
LoseACXP / S&P ACXP unavailable / -27.11% |
| 2020-Q10/3 |
LoseACXP / S&P ACXP unavailable / -19.60% |
LoseACXP / S&P ACXP unavailable / 3.47% |
LoseACXP / S&P ACXP unavailable / -14.75% |
| 2019-Q40/3 |
LoseACXP / S&P ACXP unavailable / 9.07% |
LoseACXP / S&P ACXP unavailable / 5.36% |
LoseACXP / S&P ACXP unavailable / 2.99% |
| 2019-Q30/3 |
LoseACXP / S&P ACXP unavailable / 1.70% |
LoseACXP / S&P ACXP unavailable / 5.02% |
LoseACXP / S&P ACXP unavailable / 0.21% |
| 2019-Q20/3 |
LoseACXP / S&P ACXP unavailable / 4.30% |
LoseACXP / S&P ACXP unavailable / 6.64% |
LoseACXP / S&P ACXP unavailable / 8.65% |
| 2019-Q10/3 |
LoseACXP / S&P ACXP unavailable / 13.65% |
LoseACXP / S&P ACXP unavailable / 8.12% |
LoseACXP / S&P ACXP unavailable / 14.29% |
| 2018-Q40/3 |
LoseACXP / S&P ACXP unavailable / -13.52% |
LoseACXP / S&P ACXP unavailable / 9.05% |
LoseACXP / S&P ACXP unavailable / 18.23% |
| 2018-Q30/3 |
LoseACXP / S&P ACXP unavailable / 7.71% |
LoseACXP / S&P ACXP unavailable / 10.21% |
LoseACXP / S&P ACXP unavailable / 19.06% |
| 2018-Q20/3 |
LoseACXP / S&P ACXP unavailable / 3.43% |
LoseACXP / S&P ACXP unavailable / 9.03% |
LoseACXP / S&P ACXP unavailable / 14.46% |
| 2018-Q10/3 |
LoseACXP / S&P ACXP unavailable / -0.76% |
LoseACXP / S&P ACXP unavailable / 7.68% |
LoseACXP / S&P ACXP unavailable / 12.46% |
| 2017-Q40/3 |
LoseACXP / S&P ACXP unavailable / 6.64% |
LoseACXP / S&P ACXP unavailable / 7.03% |
LoseACXP / S&P ACXP unavailable / 13.82% |
| 2017-Q30/3 |
LoseACXP / S&P ACXP unavailable / 4.48% |
LoseACXP / S&P ACXP unavailable / 5.68% |
LoseACXP / S&P ACXP unavailable / 17.57% |
| 2017-Q20/3 |
LoseACXP / S&P ACXP unavailable / 3.09% |
LoseACXP / S&P ACXP unavailable / 4.83% |
LoseACXP / S&P ACXP unavailable / 17.74% |
| 2017-Q10/3 |
LoseACXP / S&P ACXP unavailable / 6.07% |
LoseACXP / S&P ACXP unavailable / 3.67% |
LoseACXP / S&P ACXP unavailable / 13.32% |
| 2016-Q40/3 |
LoseACXP / S&P ACXP unavailable / 3.82% |
LoseACXP / S&P ACXP unavailable / 2.09% |
LoseACXP / S&P ACXP unavailable / 7.05% |
| 2016-Q30/3 |
LoseACXP / S&P ACXP unavailable / 3.85% |
LoseACXP / S&P ACXP unavailable / 0.20% |
LoseACXP / S&P ACXP unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ACXP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -68.40% | 20.78% |
| Annualized return | -68.40% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ACXP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.57% | 83.14% |
| Annualized return | -57.26% | 12.86% |
10Y · 2021-06-25 to 2026-08-27
| Metric | ACXP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.07% | 319.30% |
| Annualized return | -37.39% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |